Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...
On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...
On Monday, Eli Lilly And Co (NYSE:LLY) announced plans to boost its presence in the U.K., following a collaboration with the ...
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
The Lilly Ledbetter Fair Play Act plugged a loophole that foiled her wage discrimination claims against Goodyear and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback